Serum Adiponectin in Chinese Population and Its Correlation to Cardiovascular and Cerebrovascular Diseases

Myocardial Infarction Clinical Trial

Official title:

Serum Adiponectin Concentration, Activity and Isoforms in Chinese Population and Its Correlation to Cardiovascular and Cerebrovascular Diseases

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT01372800
• Other study ID #: xj050503
• Status: Recruiting
• Phase: N/A
• First received: June 10, 2011
• Last updated: November 19, 2013
• Start date: May 2011

Study information

• Verified date: November 2011
• Source: Xijing Hospital
• Contact: Ling Tao, M.D Ph.D
• Phone: +86-15002955798
• Email: lingtao2006[@]gmail.com
• Is FDA regulated: No
• Health authority: China: Food and Drug Administration
• Study type: Observational

Clinical Trial Summary

Adiponectin (Ad) is an abundant protein in human body, and reports have shown that it act as a novel risk factor for brain and heart ischemia injury. This 5 years follow-up study will focus on serum adiponectin concentration, activity and isoforms in Chinese population and its correlation to these diseases.

Description:

Adiponectin (Ad) is an abundant protein hormone regulatory of numerous metabolic processes, anti-inflammatory, vascular protective, and anti-ischemic properties. Since its 1995 discovery, Ad has garnered considerable attention for its role in diabetic and cardiovascular pathology. Clinical observations have demonstrated the association of hypoadiponectinemia in patients with obesity, cardiovascular disease, and insulin resistance. There is growing evidence supporting Ad can act as a novel risk factor for cardiovascular and cerebrovascular injury. This 5 years follow-up study will focus on serum adiponectin concentration, activity and isoforms in Chinese population and its correlation to cardiovascular and cerebrovascular diseases.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30000
• Est. primary completion date: October 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

• available for 5 years of follow-up study

Exclusion Criteria:

• Death caused other than cardiovascular and cerebralvascular diseases till the study ends

• Floating Population

• Pregnancy, lactation, or child bearing women

• Tumor

• Active hepatic disease or hepatic dysfunction, or AST/ALT > 1.5UNL

• Severe renal dysfunction(Scr > 3 mg/dl or 264µmol/L)

• Patients with any condition which, in the investigator's judgment, might increase the risk to the subject for any adverse event or abnormal laboratory finding

Study Design

Observational Model: Cohort, Time Perspective: Prospective

Related Conditions & MeSH terms

• Cerebral Infarction
• Cerebrovascular Disorders
• Infarction
• Myocardial Infarction

Locations

Country	Name	City	State
China	Xijing Hospital	Xi'an	Shaanxi

Sponsors (1)

Lead Sponsor	Collaborator
Xijing Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants with major adverse events	Major adverse events included but were not limited to death during the study caused by cardiovascular events or cerebrovascular events.	5 years	Yes
Secondary	blood routine, glucose and lipid profile; ECG;	the tests mentioned above will be taken once per year	5 years	No
Secondary	serum adiponectin concentration, activity and isoforms	serum adiponectin concentration, activity and isoforms will be monitored once per year.	5 years	No